Preferred Label : MVF-HER-2(597-626)/MVF-HER-2 (266-296) Peptide Vaccine;
NCIt definition : A combination peptide vaccine of 2 chimeric peptides of the promiscuous T cell epitope
derived from measles virus fusion protein (MVF; amino acid residues 288-302) co-synthesized
with B-cell epitopes derived from the HER-2/neu a.a. 597-626 and HER-2/neu a.a. 266-296,
with potential antineoplastic activity. Vaccination with MVF-HER-2(597-626)/MVF-HER-2(266-296)
peptide vaccine may be capable of inducing an active specific immune response, mounting
a cytotoxic T-lymphocyte (CTL) response and an antibody-dependent cell-mediated cytotoxicity
(ADCC) against tumor cells that overexpress the HER-2 protein. The oncogenic protein
HER-2, a member of the human epidermal growth factor receptor (EGFR) family of tyrosine
kinases, is overexpressed in a variety of cancers and is correlated with increased
tumor growth, progression and a poor prognosis. HER-2(597-626) corresponds to the
binding site of trastuzumab on the extracellular domain IV of HER-2; HER-2 (266-296)
corresponds to the binding site of pertuzumab on the dimerization loop of domain II
of HER-2.;
NCI Metathesaurus CUI : CL429828;
Origin ID : C97344;
UMLS CUI : C3273368;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
